Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?

Significant research has been conducted to better understand the extensive, heterogeneous molecular features of triple-negative breast cancer (TNBC). We reviewed published TNBC molecular classifications to identify major groupings that have potential for clinical trial development. With the ultimate...

Full description

Bibliographic Details
Main Authors:	Le Du, Fanny, Eckhardt, Bedrich L., Lim, Bora, Litton, Jennifer K., Moulder, Stacy, Meric-Bernstam, Funda, Gonzalez-Angulo, Ana M., Ueno, Naoto T.
Format:	Online
Language:	English
Published:	Impact Journals LLC 2015
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4536987/

id	pubmed-4536987
recordtype	oai_dc
spelling	pubmed-45369872015-08-26 Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype? Le Du, Fanny Eckhardt, Bedrich L. Lim, Bora Litton, Jennifer K. Moulder, Stacy Meric-Bernstam, Funda Gonzalez-Angulo, Ana M. Ueno, Naoto T. Review Significant research has been conducted to better understand the extensive, heterogeneous molecular features of triple-negative breast cancer (TNBC). We reviewed published TNBC molecular classifications to identify major groupings that have potential for clinical trial development. With the ultimate aim to streamline translational medicine, we linked these categories of TNBC according to their gene-expression signatures, biological function, and clinical outcome. To this end, we define five potential clinically actionable groupings of TNBC: 1) basal-like TNBC with DNA-repair deficiency or growth factor pathways; 2) mesenchymal-like TNBC with epithelial-to-mesenchymal transition and cancer stem cell features; 3) immune-associated TNBC; 4) luminal/apocrine TNBC with androgen-receptor overexpression; and 5) HER2-enriched TNBC. For each defined subtype, we highlight the major biological pathways and discuss potential targeted therapies in TNBC that might abrogate disease progression. However, many of these potential targets need clinical validation by clinical trials. We have yet to know how we can enrich the targets by molecular classifications. Impact Journals LLC 2015-05-07 /pmc/articles/PMC4536987/ /pubmed/25973541 Text en Copyright: © 2015 Le Du et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Le Du, Fanny Eckhardt, Bedrich L. Lim, Bora Litton, Jennifer K. Moulder, Stacy Meric-Bernstam, Funda Gonzalez-Angulo, Ana M. Ueno, Naoto T.
spellingShingle	Le Du, Fanny Eckhardt, Bedrich L. Lim, Bora Litton, Jennifer K. Moulder, Stacy Meric-Bernstam, Funda Gonzalez-Angulo, Ana M. Ueno, Naoto T. Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?
author_facet	Le Du, Fanny Eckhardt, Bedrich L. Lim, Bora Litton, Jennifer K. Moulder, Stacy Meric-Bernstam, Funda Gonzalez-Angulo, Ana M. Ueno, Naoto T.
author_sort	Le Du, Fanny
title	Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?
title_short	Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?
title_full	Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?
title_fullStr	Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?
title_full_unstemmed	Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?
title_sort	is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?
description	Significant research has been conducted to better understand the extensive, heterogeneous molecular features of triple-negative breast cancer (TNBC). We reviewed published TNBC molecular classifications to identify major groupings that have potential for clinical trial development. With the ultimate aim to streamline translational medicine, we linked these categories of TNBC according to their gene-expression signatures, biological function, and clinical outcome. To this end, we define five potential clinically actionable groupings of TNBC: 1) basal-like TNBC with DNA-repair deficiency or growth factor pathways; 2) mesenchymal-like TNBC with epithelial-to-mesenchymal transition and cancer stem cell features; 3) immune-associated TNBC; 4) luminal/apocrine TNBC with androgen-receptor overexpression; and 5) HER2-enriched TNBC. For each defined subtype, we highlight the major biological pathways and discuss potential targeted therapies in TNBC that might abrogate disease progression. However, many of these potential targets need clinical validation by clinical trials. We have yet to know how we can enrich the targets by molecular classifications.
publisher	Impact Journals LLC
publishDate	2015
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4536987/
_version_	1613259858294865920

Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?

Similar Items